Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17129152 | 0.83 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL3047470 | 0.83 | DUT (0.33) | PREP | |
| SCHEMBL6276455 | 0.81 | TSHR (0.40) | — | |
| SCHEMBL4192095 | 0.79 | RAB9A (0.46) | ESR1ESR2 | |
| SCHEMBL2981195 | 0.79 | TRPA1 (0.33) | MEN1KMT2APREP | |
| SCHEMBL12032259 | 0.78 | KIF11 (0.44) | PREP | |
| SCHEMBL9701756 | 0.76 | DUT (0.36) | MEN1KMT2A | |
| SCHEMBL3868128 | 0.75 | MGLL (0.39) | — | |
| SCHEMBL15400428 | 0.75 | EPHX2 (0.35) | MEN1KMT2A | |
| SCHEMBL1082657 | 0.74 | SRD5A2 (0.45) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852863-B2 | Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1470109-A1 | METABOLITES OF (3- [(4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL -PHENOXY)-ACETIC ACID | Pfizer Products Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | CAMERON KIMBERLY O (US) | 2003-11-20 | — | — | US | disclosed |
| WO-2003064391-A1 | METABOLITES OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | ABAT, BCAT2, PC | ESR1 2132/4885ESR2 2670/4885MEN1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.